Skip to content

The VIGORous Physical Activity for Glycaemic Control in Type 1 Diabetes (VIGOR) Trial

The VIGORous Physical Activity for Glycaemic Control in Type 1 Diabetes (VIGOR) Trial

Status
Terminated
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01834144
Acronym
VIGOR
Enrollment
4
Registered
2013-04-17
Start date
2013-05-31
Completion date
2015-06-15
Last updated
2018-09-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Type 1 Diabetes

Keywords

Type 1 Diabetes, Hypoglycaemia, Glycaemic variability, Vigorous Intensity Physical Activity, Continuous Glucose Monitoring

Brief summary

Background/Justification: Regular physical activity (PA) has substantial health benefits in persons with type 1 diabetes (T1D), including reduced risk of complications and cardiovascular mortality. Despite these benefits, individuals with T1D remain significantly less active than their peers without diabetes. Two major factors likely explain the low rates of PA in young people with T1D: (1) fear of post-exercise hypoglycaemia, particularly nocturnal hypoglycaemia, and (2) a lack of empirical evidence for the efficacy of PA for achieving optimal glycaemic control. A number of acute exercise trials recently demonstrated that the inclusion of vigorous intensity PA in conventional moderate intensity (i.e. walking) PA sessions may overcome these limitations. No studies have tested the efficacy of high intensity PA for reducing the risk of exercise-related hypoglycaemia or glycaemic variability in a randomized controlled trial (RCT). Study Hypotheses: In persons 15-35 years of age living with T1D, this study will test the hypotheses that (1) the addition of intermittent vigorous intensity PA to a moderate intensity intervention will reduce the time spent in hypoglycaemia in the 12 hour period following exercise and (2) the addition of intermittent vigorous intensity PA to a moderate intensity PA intervention will elicit significant improvements in glycemic excursions, as measured by the Mean Amplitude of Glycaemic Excursions (MAGE), in the 12-hour period following exercise.We are also exploring the hypothesis that reducing the risk of hypoglycemia will lead to a sustained increase in physical activity one year after randomization.

Interventions

OTHERExercise Training

Sponsors

Manitoba Institute of Child Health
CollaboratorINDUSTRY
University of Manitoba
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
OTHER
Masking
SINGLE (Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
15 Years to 45 Years
Healthy volunteers
No

Inclusion criteria

* Age: 15-45 years old * Have lived with type 1 diabetes for at least 2 years * HbA1c \<9.9% * Currently physically inactive (\<150 minutes of self-reported structured physical activity per week) * Undergone a resting ECG to screen for left ventricular hypertrophy, arrhythmias or signs or coronary artery disease that may be exacerbated with vigorous intensity exercise

Exclusion criteria

* Have frequent and unpredictable hypoglycaemia * Had a change in insulin management strategy, including adoption of a pump, within 2 months of enrolment * Are currently participating in structured activity or sport-related activities * Are women who are pregnant or planning to get pregnant within the 12 months of the trial and those who are breastfeeding * Have conditions that would render physical activity contraindicated including: uncontrolled hypertension (BP\>150mmHg systolic or \>95mmHg diastolic in a sitting position); severe peripheral neuropathy; history of cardiovascular disease * Have a cognitive deficit resulting in an inability to provide informed consent * Currently taking beta blockers * Currently taking atypical antipsychotics or corticosteroids

Design outcomes

Primary

MeasureTime frame
Time Spent in Hypoglycaemia in the 12-hour Period Following Exercise, Defined as an Interstitial Glucose Reading <4.0mmol/L and Measured by Continuous Glucose Monitor.Measured at baseline, and 1, 8,16 and 52 weeks following randomization

Secondary

MeasureTime frame
Glycaemic Variability, Measured by the Mean Amplitude of Glycaemic Excursions (MAGE), in the 12-hour Period Following Exercise. This is Calculated From the Same Continuous Glucose Monitor Data as the Primary Outcome.Measured at baseline, and 1, 8, 16 and 52 weeks following randomization

Countries

Canada

Participant flow

Participants by arm

ArmCount
Moderate Intensity Exercise
150-200 minutes of weekly moderate intensity exercise (45-55% of peak fitness) Exercise Training
1
Moderate + Vigorous Intensity Exercise
150-200 minutes of weekly moderate intensity exercise, with short bouts of vigorous intensity exercise (80-90% of peak fitness) Exercise Training
3
Total4

Baseline characteristics

CharacteristicModerate Intensity ExerciseModerate + Vigorous Intensity ExerciseTotal
Age, Continuous0 years
STANDARD_DEVIATION 0
0 years
STANDARD_DEVIATION 0
0 years
STANDARD_DEVIATION 0
Race and Ethnicity Not Collected0 Participants
Sex: Female, Male
Female
0 Participants0 Participants0 Participants
Sex: Female, Male
Male
0 Participants0 Participants0 Participants

Adverse events

Event typeEG000
affected / at risk
EG001
affected / at risk
deaths
Total, all-cause mortality
— / —— / —
other
Total, other adverse events
0 / 10 / 3
serious
Total, serious adverse events
0 / 10 / 3

Outcome results

Primary

Time Spent in Hypoglycaemia in the 12-hour Period Following Exercise, Defined as an Interstitial Glucose Reading <4.0mmol/L and Measured by Continuous Glucose Monitor.

Time frame: Measured at baseline, and 1, 8,16 and 52 weeks following randomization

Secondary

Glycaemic Variability, Measured by the Mean Amplitude of Glycaemic Excursions (MAGE), in the 12-hour Period Following Exercise. This is Calculated From the Same Continuous Glucose Monitor Data as the Primary Outcome.

Time frame: Measured at baseline, and 1, 8, 16 and 52 weeks following randomization

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026